Physician profile
Deirdre Lawson
NPI 1225132699
$1,232.81
in general payments reported to CMS, 2019-2025
23 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $28.64 · 2021: $49.38 · 2022: $109 · 2023: $282 · 2024: $382 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $897.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $190.19 | 2023-2025 | Dovato, Cabenuva, Apretude |
| Lilly USA, LLC | $153.92 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $110.45 | 2019-2025 | |
| Amgen INC. | $87.23 | 2022-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $81.60 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.91 | 2019-2024 | Jardiance |
| Dexcom, INC. | $68.40 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $55.26 | 2025 | |
| Merck Sharp & Dohme LLC | $49.85 | 2023-2024 | Verquvo, Steglatro, Belsomra |
| Xeris Pharmaceuticals, INC. | $39.50 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $38.46 | 2022-2023 | |
| Sanofi Pasteur INC. | $37.40 | 2023 | |
| Exact Sciences Corporation | $35.04 | 2024 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $32.38 | 2024 | Aptima |
| Astrazeneca Pharmaceuticals LP | $30.34 | 2020-2024 | Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $29.69 | 2025 | |
| Sunovion Pharmaceuticals INC. | $20.06 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $19.37 | 2025 | |
| Neurocrine Biosciences, INC. | $18.27 | 2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $15.90 | 2019 | |
| Eisai INC. | $14.40 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2022 | |
| Glaxosmithkline, LLC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deirdre Lawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.